Why Did Propanc Biopharma Stock Soar 27.25%?

On August 20, 2025, Propanc Biopharma's stock surged by 27.25% in pre-market trading, marking a significant rise in investor interest and confidence in the company's future prospects.

Propanc Biopharma recently closed a public offering of 1,000,000 shares of its common stock at $4.00 per share, raising a total of $4 million. This capital infusion is expected to support the company's general business activities and strategic initiatives, particularly in the development of its cancer therapies.

The company's decision to uplist to the Nasdaq exchange is a strategic move aimed at enhancing its credibility and liquidity. This transition is likely to attract more institutional investors and provide a more stable trading environment, further boosting investor confidence in Propanc Biopharma's growth potential.